Index of artpub/2021/264650/

Wierda, W. G
Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia : Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
2021
https://ddd.uab.cat/record/264650